Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Amino Acids, Branched-Chain | 1 | 2023 | 264 | 0.700 |
Why?
|
Diet, Mediterranean | 1 | 2023 | 735 | 0.550 |
Why?
|
Proteomics | 4 | 2024 | 3817 | 0.540 |
Why?
|
Foramen Ovale, Patent | 1 | 2018 | 214 | 0.500 |
Why?
|
Tricuspid Valve | 1 | 2016 | 409 | 0.430 |
Why?
|
Endocarditis | 1 | 2016 | 351 | 0.400 |
Why?
|
Allied Health Personnel | 1 | 2013 | 156 | 0.390 |
Why?
|
Thromboembolism | 1 | 2018 | 1017 | 0.380 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 2061 | 0.310 |
Why?
|
Placebos | 1 | 2013 | 1668 | 0.310 |
Why?
|
Exercise | 5 | 2024 | 5787 | 0.300 |
Why?
|
Medical Records | 1 | 2013 | 1407 | 0.290 |
Why?
|
Respiration, Artificial | 1 | 2018 | 2622 | 0.280 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2018 | 1459 | 0.280 |
Why?
|
Echocardiography | 2 | 2016 | 4981 | 0.280 |
Why?
|
HIV Long Terminal Repeat | 1 | 2005 | 85 | 0.260 |
Why?
|
Gene Products, tat | 1 | 2005 | 111 | 0.260 |
Why?
|
Sepsis | 1 | 2019 | 2592 | 0.240 |
Why?
|
Orthopedics | 1 | 2013 | 892 | 0.230 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5889 | 0.230 |
Why?
|
Persea | 1 | 2023 | 18 | 0.220 |
Why?
|
Hypertension | 2 | 2024 | 8594 | 0.210 |
Why?
|
Hospital Mortality | 1 | 2016 | 5425 | 0.200 |
Why?
|
Secondary Prevention | 2 | 2018 | 1548 | 0.190 |
Why?
|
Blood Proteins | 2 | 2024 | 1173 | 0.190 |
Why?
|
Anti-Bacterial Agents | 1 | 2019 | 7408 | 0.180 |
Why?
|
Immunoglobulin Fc Fragments | 2 | 2012 | 280 | 0.170 |
Why?
|
Virus Replication | 1 | 2005 | 2432 | 0.150 |
Why?
|
Biomedical Research | 1 | 2013 | 3426 | 0.150 |
Why?
|
Melanoma, Experimental | 2 | 2012 | 562 | 0.140 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15757 | 0.140 |
Why?
|
Research Design | 1 | 2013 | 6180 | 0.140 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 8056 | 0.140 |
Why?
|
Metabolome | 1 | 2023 | 982 | 0.130 |
Why?
|
Blood Pressure | 2 | 2024 | 8525 | 0.130 |
Why?
|
Stroke | 1 | 2018 | 9962 | 0.130 |
Why?
|
RNA | 1 | 2005 | 2722 | 0.130 |
Why?
|
Kinetics | 1 | 2023 | 6377 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2023 | 12293 | 0.120 |
Why?
|
Peptide Fragments | 2 | 2012 | 5125 | 0.120 |
Why?
|
Genetic Vectors | 4 | 2012 | 3380 | 0.120 |
Why?
|
Hepatitis B Surface Antigens | 2 | 2012 | 301 | 0.110 |
Why?
|
Cancer Vaccines | 2 | 2012 | 1046 | 0.110 |
Why?
|
Unnecessary Procedures | 1 | 2016 | 413 | 0.110 |
Why?
|
Humans | 20 | 2024 | 760621 | 0.100 |
Why?
|
Middle Aged | 9 | 2024 | 220352 | 0.090 |
Why?
|
Risk Factors | 6 | 2024 | 74359 | 0.090 |
Why?
|
Health Status | 1 | 2023 | 4081 | 0.090 |
Why?
|
Hepatitis B Vaccines | 1 | 2011 | 186 | 0.090 |
Why?
|
Anti-HIV Agents | 1 | 2005 | 4491 | 0.080 |
Why?
|
Male | 11 | 2024 | 359744 | 0.080 |
Why?
|
Sample Size | 1 | 2013 | 840 | 0.080 |
Why?
|
Thrombolytic Therapy | 1 | 2018 | 2108 | 0.080 |
Why?
|
I-kappa B Kinase | 1 | 2010 | 251 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2023 | 3959 | 0.080 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2010 | 268 | 0.070 |
Why?
|
Atherosclerosis | 1 | 2023 | 3517 | 0.070 |
Why?
|
Influenza, Human | 1 | 2018 | 1528 | 0.070 |
Why?
|
Observer Variation | 1 | 2013 | 2601 | 0.070 |
Why?
|
Oxidoreductases | 1 | 2009 | 412 | 0.070 |
Why?
|
Hepatitis B, Chronic | 1 | 2011 | 403 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2016 | 2283 | 0.070 |
Why?
|
Aged | 7 | 2024 | 169152 | 0.060 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 119 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6544 | 0.060 |
Why?
|
Dependovirus | 1 | 2010 | 709 | 0.060 |
Why?
|
Adult | 6 | 2024 | 219994 | 0.060 |
Why?
|
Acute Coronary Syndrome | 1 | 2018 | 2365 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2013 | 20080 | 0.060 |
Why?
|
Female | 9 | 2024 | 391270 | 0.060 |
Why?
|
Massachusetts | 2 | 2016 | 8803 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2023 | 12626 | 0.060 |
Why?
|
Lentivirus | 3 | 2012 | 506 | 0.060 |
Why?
|
Obesity | 2 | 2023 | 12922 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 2696 | 0.050 |
Why?
|
Reoperation | 1 | 2013 | 4291 | 0.050 |
Why?
|
Transduction, Genetic | 1 | 2005 | 897 | 0.050 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2013 | 1370 | 0.050 |
Why?
|
Anticoagulants | 1 | 2018 | 4897 | 0.050 |
Why?
|
Microscopy, Electron | 1 | 2005 | 2558 | 0.050 |
Why?
|
NF-kappa B | 1 | 2010 | 2488 | 0.050 |
Why?
|
Glucose | 2 | 2023 | 4351 | 0.050 |
Why?
|
Biology | 1 | 2023 | 290 | 0.050 |
Why?
|
Antigens, Neoplasm | 1 | 2009 | 1998 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 5496 | 0.050 |
Why?
|
Physical Endurance | 1 | 2023 | 363 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10827 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2012 | 4353 | 0.040 |
Why?
|
Computer Simulation | 1 | 2013 | 6218 | 0.040 |
Why?
|
Insulin | 2 | 2023 | 6597 | 0.040 |
Why?
|
HIV | 1 | 2005 | 1579 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 3707 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2023 | 1843 | 0.040 |
Why?
|
Binding Sites | 1 | 2005 | 6048 | 0.030 |
Why?
|
Exercise Test | 1 | 2024 | 2128 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2009 | 4550 | 0.030 |
Why?
|
Genome | 1 | 2023 | 1739 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2010 | 4925 | 0.030 |
Why?
|
Immunotherapy | 1 | 2011 | 4642 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2005 | 5785 | 0.030 |
Why?
|
Heart Failure | 1 | 2018 | 11847 | 0.030 |
Why?
|
Incidence | 2 | 2024 | 21392 | 0.030 |
Why?
|
Homeostasis | 1 | 2023 | 3306 | 0.020 |
Why?
|
Cell Line | 1 | 2005 | 15620 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2013 | 15697 | 0.020 |
Why?
|
Mice, Inbred mdx | 1 | 2010 | 88 | 0.020 |
Why?
|
Hepatitis B Antibodies | 1 | 2011 | 157 | 0.020 |
Why?
|
Mice | 5 | 2023 | 81208 | 0.020 |
Why?
|
Mice, Inbred C57BL | 3 | 2012 | 22023 | 0.020 |
Why?
|
Blood Glucose | 1 | 2023 | 6381 | 0.020 |
Why?
|
Outpatients | 1 | 2016 | 1607 | 0.020 |
Why?
|
Vaccines, Synthetic | 1 | 2011 | 617 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3725 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2016 | 80372 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2754 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16546 | 0.020 |
Why?
|
Animals | 5 | 2023 | 167963 | 0.020 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2009 | 824 | 0.020 |
Why?
|
Gene Transfer Techniques | 1 | 2010 | 1204 | 0.020 |
Why?
|
Autoantigens | 1 | 2009 | 877 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2009 | 2471 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2018 | 12427 | 0.010 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2009 | 1088 | 0.010 |
Why?
|
Prospective Studies | 2 | 2018 | 54303 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2012 | 4264 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2011 | 3735 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 25942 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2010 | 2907 | 0.010 |
Why?
|
Regeneration | 1 | 2010 | 1506 | 0.010 |
Why?
|
Cohort Studies | 1 | 2024 | 41335 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2009 | 5870 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2011 | 9530 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2012 | 3075 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39261 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2012 | 14372 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2011 | 10181 | 0.010 |
Why?
|
Inflammation | 1 | 2012 | 10756 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2018 | 65017 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2010 | 18137 | 0.010 |
Why?
|
United States | 1 | 2018 | 72461 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 13630 | 0.010 |
Why?
|
Signal Transduction | 1 | 2010 | 23376 | 0.000 |
Why?
|
Mutation | 1 | 2009 | 29932 | 0.000 |
Why?
|
Concepts
(143)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(27)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_